Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153966 · ClinicalTrials.gov registry record · Phase 1
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
A Phase 1 study of Prion Disease, sponsored by Ionis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 13
- Study locations
NCT06153966 is a Phase 1 study of Prion Disease that is actively recruiting participants, run by Ionis Pharmaceuticals. The registered enrollment target is 76 participants. The trial reports 13 study locations across 8 states.
The verdict
NCT06153966, a Phase 1 study of Prion Disease, is actively recruiting participants, sponsored by Ionis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ION717
Study Locations (13)
Other
- Royal Melbourne Hospital - Parkville
- Hôpital Universitaire Pitié Salpêtrière - Paris
- University Medical Center Göttingen - Göttingen
- Tel Aviv Sourasky Medical Center - Tel Aviv
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta - Milan
- Hospital Clinic De Barcelona - Barcelona
Massachusetts
- Massachusetts General Hospital - Boston
New York
- NYU Langone Health - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Quebec
- McGill University Health Centre - Montreal
Isesaki-shi
- Mihara Memorial Hospital - Gunma
Kodaira-shi
- National Center of Neurology and Psychiatry - Tokyo
Shimonoseki-shi
- Neuromuscular Center Yoshimizu Hospital - Yamaguchi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06153966
The ClinicalTrials.gov registry entry for NCT06153966 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prion Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06153966 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06153966 about?
NCT06153966 is a clinical study titled "PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
What is the current status of trial NCT06153966?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2024-01-04. Estimated completion is 2030-06.
What conditions does trial NCT06153966 study?
This clinical trial studies the following conditions: Prion Disease.
What interventions are being tested in trial NCT06153966?
The interventions under investigation include: Placebo (DRUG), ION717 (DRUG).
Who is sponsoring clinical trial NCT06153966?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153966 being conducted?
This trial has 13 study locations across Massachusetts, New York, Ohio, Quebec, Isesaki-shi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.